Recently, Wondfo's fully automated IHC staining system and secondary antibody products have received IVDR CE certification. As a fully self-developed product, Wondfo's pathology diagnostic products have been recognized both domestically and internationally for their excellent performance and high quality. The recent IVDR CE certification further confirms Wondfo's capability to provide high-standard pathology diagnostic products globally, effectively improving the work efficiency of the pathology department..

 
Fully Self-Developed and Manufactured
 
In July 2024, Wondfo's PMS2 antibody (2E7-C3) received Optimal certification from NordiQC, an internationally recognized External Quality Assessment (EQA) for pathology. This certification affirms the high quality of Wondfo's complete solution, which includes the fully automated IHC staining system and process.

 
· One Machine can Perform Several Functions
 
Through its highly automated design, the multifunctional staining system significantly simplifies the complex process of traditional immunohistochemistry staining and is highly expandable, capable of completing a variety of staining procedures at the same time, which significantly reduces manual intervention and improves work efficiency.
 
· Multiple Patented Technologies Enhance Performance
 
Patented technologies such as independent temperature control for each slide, solid-liquid cover technology, wavelike-mixing technology, and RFID chip recognition enhance staining quality and efficiency.
 
· Self-Developed Unique Secondary Antibody System
 
Wondfo's ultra-sensitive HRP enzyme-conjugated secondary antibody framework features a unique "clover-like" structure, offering high sensitivity, strong specificity, and stable staining.
 
 
Since its establishment in 2018, Wondfo's pathology diagnostic technology platform has expanded into various sectors including tissue pathology, cytopathology, molecular pathology, and digital pathology, focusing on the development of key technologies and products. The platform has received dozens of patents and over 300 reagents approved for market release.
 
Upholding the mission of "making pathology diagnosis simpler," Wondfo's pathology diagnostic technology platform aims to drive innovation and product upgrades in pathology diagnostics through a comprehensive solution, collaborating with partners worldwide to contribute greater wisdom and strength to global pathology diagnostics.